ANALYST AVAILABLE TO COMMENT ON THE MARKET FORECAST FOR THE DRUG
WALTHAM, Mass., Oct. 12 /PRNewswire/ -- Dr. Sylvia Eash, Ph.D., analyst at Decision Resources, is available to discuss the impact of the Food and Drug Administration's (FDA) possible approval of Merck's Isentress, the first integrase inhibitor drug which blocks the ability of the HIV virus to replicate and infect new cells.
Integrase inhibitors are a novel class of HIV drugs aimed at a previously unexploited viral target. They are a key new class that will expand therapeutic options for HIV patients and stand out as one of the most promising emerging classes in development for HIV. The reported efficacy and safety data from clinical trials of Isentress indicate that the product is highly efficacious, safe, well tolerated in both treatment-naive and treatment-experienced HIV patients. The clinical data on Isentress presented to date suggests that there is significant opportunity for follow-on agents in this new class of HIV drugs.
Isentress is expected to launch during the fourth quarter of 2007, according to Merck.
Dr. Eash can provide:
-- Insight on the class of integrase inhibitors and particularly Isentress
and its potential effect on other drugs in the HIV market.
-- Key factors that will have an impact on Isentress's uptake and use. How
will Isentress be positioned in the lines of HIV treatment?
-- The main drivers and barriers for its use. What is the forecast for
Isentress? Which drugs will be its main competition?
-- Key thought leaders' perceptions about Isentress.
-- Isentress's impact on the HIV market and on the overall HIV therapeutic
Sylvia Eash, Ph.D., is an analyst with Decision Resources Infectious
Disease group, where she evaluates emerging therapies and develops market
forecasts. She has a doctoral degree in pathobiology from Brown University.
Dr. Eash is the author of
|SOURCE Decision Resources|
Copyright©2007 PR Newswire.
All rights reserved